Home News Page 61

News

Photo: Piramal combines individualized service with unparalleled speed and flexibility to manufacture parenteral drug products in liquid and lyophilized dosage forms. Unique mobile isolator technology within FDA-approved sterile manufacturing facility ensures product containment for potent and cytotoxic compounds and radio-labeled products. Photo courtesy: Piramal Pharma Solutions/Coldstream Laboratories, Lexington, Kentucky.

Piramal ‘Snatches up’ Kentucky based Coldstream Laboratories

Mumbai (India) based Piramal Enterprises Limited, a member of the Primal Group led by Ajay G. Piramal, one of...

Heidelberg Pharma Receives Research Grant for the Development of PSMA Antibody-drug Conjugate

Heidelberg Pharma, a subsidiary WILEX AG based in Ladenburg, Germany which primarily advances the development of innovative platform technologies for...

Mersana and Takeda Expand Antibody-Drug Conjugate Partnership

Mersana Therapeutics Inc, based in Cambridge, MA, USA and Takeda Pharmaceutical Company Limited have expanded their ongoing collaboration to...

Seattle Genetics and Bristol-Myers Squibb Evaluate Combination of Brentuximab Vedotin and Nivolumab

Seattle Genetics, Inc. and Bristol-Myers Squibb Company have entered into a clinical trial collaboration to evaluate the investigational combination...

Blend Therapeutics Appoints New Member to It’s Board of Directors and Secures US $21...

Earlier today, Blend Therapeutics, a biopharmaceutical company based in Watertown, MA involved in the discovery of new classes of...

Sacituzumab Govitecan (IMMU-132) Receives FDA Fast Track Designation for Triple-Negative Breast Cancer Therapy

The U.S. Food and Drug Administration (FDA) designating as a Fast Track development program the investigation of sacituzumab govitecan...

Compugen’s Pipeline for Oncology to be Further Expanded and Diversified

Compugen Ltd., a Tel Aviv, Israel, based leading drug discovery company focused on monoclonal antibodies and therapeutic proteins to...

MI130004, a New ADC Using a Marine Compound, Shows Promising Therapeutic Profile in Animal...

Over the last decade, antibody–drug conjugates or ADCs have emerged as powerful tool for the treatment of patients with...

Pfizer and Philogen Develop & Commercialize Antibody-drug Conjugates

Philogen, a Swiss-Italian clinical-stage biotechnology company based in Sienna, Italy, engaged in the discovery and development of novel biopharmaceutical products including...

Preclinical Data Confirms Therapeutic Potential of SYD985 in Patients with Low Levels of HER2...

Preclinical data of SYD985, presented by Synthon Biopharmaceutical's Gijs Verheijden during the 37th Annual San Antonio Breast Cancer Symposium...